Search PubMed⌕ Search

Biomedical subjects

Junyan Xu

Publications and source records attributed to Junyan Xu.

2 recordsLinked to original sources

Germline ATBF1 mutations and prostate cancer risk.

BACKGROUND: ATBF1 has been recently identified as a candidate prostate tumor suppressor gene. In addition to more unique mutations, two somatic mutations (shortening of a polypyrimidine tract [Poly(T)n] and a deletion beginning at codon 3381 (3381del)) were each observed in multiple prostate cancer samples and both appear to have an impact on ATBF1 gene function and expression. METHODS: We assayed two recurrent sequence variants in germline DNA from prostate cancer cases and controls, and examined whether carriers of these variants are at increased risk for prostate cancer. RESULTS: We found Poly(T)n variants in both normal and matched tumor DNA samples from multiple patients, indicating a germline origin in each case. Genotyping germline DNA samples indicated that 3381del was significantly associated with prostate cancer risk among sporadic cases (P = 0.03), but not among men with hereditary disease. CONCLUSIONS: Our study indicates that the germline 3381del allele may influence prostate cancer susceptibility.

Alleles↗

[Radiofrequency ablation for treatment of nasal obstruction secondary to inferior turbinate hypertrophy].

OBJECTIVE: To assess the efficacy of bipolar radiofrequency ablation on inferior turbinate in patients with nasal obstruction caused by inferior turbinate hypertrophy. METHOD: Eighteen patients enrolled in the study and bipolar radiofrequency ablation was delivered to inferior turbinate. The preoperative and postoperative nasal obstruction were investigated by visual analogue scale (VAS). RESULT: All patients were improved in 3 months. Mean obstruction(VAS) improved from 70.5% +/- 10.5% to 53.3% +/- 11.6% (right side), and from 67.7% +/- 9.4% to 45.0% +/- 9.2% (left side). CONCLUSION: The use of radiofrequency for submucosal tissue ablation in the hypertrophied inferior turbinate is an effective modality for reducing symptoms of nasal obstruction.

Adult↗